Figure 2From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study Kaplan-Meier estimates of progression free survival. The median progression-free survival was 6.9 months (95% CI (5.9, 10.3)) in the capecitabine 1750 mg/m2 group and 8.4 months (95% CI(5.2, 12.4)) in the capecitabine 1500 mg/m2 group.Back to article page